Skip to Content

Icon PLC

ICLR: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$974.00SdbcbFzkmljdl

Icon Continues to Benefit From Increased Clinical Trial Outsourcing Demand

Business Strategy and Outlook

We believe Icon possesses all the necessary elements to win share in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ICLR so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center